Table 4.

Annual rates of site-specific invasive cancer cases other than breast and uterine cancer—NSABP STAR Trial (P-2)

Site of cancerEvents, nRate per 1000RR*RR (95% CI)
TamoxifenRaloxifeneTamoxifenRaloxifeneDifference
Adrenal gland0100.02−0.02
Bone/cartilage/connective tissue340.050.06−0.011.320.22–8.98
Buccal cavity and pharynx460.060.10−0.041.480.35–7.13
Cervix300.0500.05
Colorectal48450.780.720.060.930.60 to 1.42
Esophagus200.0300.03
Eye110.020.0200.990.01–77.48
Gallbladder520.080.030.050.390.04–2.41
Kidney14210.230.34−0.111.480.72–3.15
Larynx0100.02−0.02
Leukemia/other lymph/hemato60530.970.850.120.870.59–1.28
Liver720.110.030.080.280.03–1.48
Lung, trachea, bronchus57640.921.02−0.101.110.76–1.61
Nasal/middle ear/sinuses110.020.0200.990.01–77.48
Nervous system9100.150.16−0.011.100.40–3.05
Other gyn220.030.0300.990.07–13.62
Ovary21340.500.79−0.291.580.89–2.86
Pancreas12110.190.180.010.900.36–2.24
Retroperitoneum740.110.060.050.560.12–2.22
Skin25240.400.380.020.950.52–1.73
Small intestine0200.03−0.03
Spleen0200.03−0.03
Stomach510.080.020.060.200.004–1.76
Thyroid gland18320.290.51−0.221.760.96–3.32
Urinary bladder15120.240.190.050.790.34–1.81
Site unspecified/unspecified nature15190.240.30−0.061.250.60–2.64
Secondary/uncertain450.060.08−0.021.230.27–6.22

Abbreviations: CI, confidence interval; gyn, gynecologic; hemato, hematopoietic; lymph, lymphatic; NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

  • *Risk ratio for women in the raloxifene group compared with women in the tamoxifen group.

  • Rate in the tamoxifen group minus rate in the raloxifene group.